36 reports

  • Erythropoietin: An overview
  • Second-generation erythropoietin formulation

About Erythropoietin Drugs The global erythropoietin drugs market is expected to witness a slow growth rate during the forecast period. In 2016, EMEA dominated the market, followed by the Americas and APAC. India and China are the leading countries in the market in APAC. While Sandoz and Dr. Reddy's Laboratories dominate the...

  • Erythropoietin
  • World
  • Forecast
  • Amgen Inc.
  • Kyowa Hakko Kirin Co., Ltd.

Global Erythropoietin Market Forecast 2017-2027 ##.

  • Biopharmaceutical
  • Erythropoietin
  • World
  • Market Size
  • 1.1 ERYTHROPOIETIN
  • ERYTHROPOIETIN RESPONSE TO HYPOXIA

Erythropoietin is a substance produced by the kidney that leads to the formation of red blood cells in the bone marrow. It is a glycoprotein hormone which regulates erythropoiesis (Red Blood Cell production). For erythrocyte precursors present in the bone marrow, EPO acts as a cytokine. Commonly referred to as hematopoietin or hemopoietin,...

  • Erythropoietin
  • World
  • Forecast
  • Market Size
  • Roche Group

## Global Erythropoietin Drug Market Outlook, By Region (2014-2022) ($MN) Table ## Global Erythropoietin Drug Market Outlook, By Product (2014-2022) ($MN) Table ## Global Erythropoietin Drug Market Outlook, By Biosimilars (2014-2022) ($MN) Table ## Global

  • Erythropoietin
  • APAC
  • Europe
  • World
  • Market Size

EPO Biosimilars - The Future of Erythropoietin Market ##.

  • Biopharmaceutical
  • Erythropoietin
  • World
  • Market Size

In addition, major players of the erythropoietin drug, along with their upcoming and anticipated erythropoietin-related products are analyzed to demonstrate how these advances might impact global erythropoietin drug market.

  • Biopharmaceutical
  • Erythropoietin
  • World
  • Forecast

European Erythropoietin Market Outlook 2022 ##.

  • Biopharmaceutical
  • Erythropoietin
  • Europe
  • Market Size
  • Global erythropoietin drugs market
  • ERYTHROPOIETIN DRUGS MARKET IN JAPAN 2014-2019 ($ MILLIONS)

About erythropoietin Erythropoietin (EPO), also referred to as hematopoietin or hemopoietin, is a glycoprotein that is responsible for the production of erythrocytes in the body. In the fetal stage, this protein is produced in the liver. However, in adulthood it is produced in the kidneys. During anemic conditions, the body produces an...

  • Erythropoietin
  • Japan
  • Chugai Pharmaceutical Co., Ltd.
  • Kissei Pharmaceutical Co., Ltd.
  • Kyowa Hakko Kirin Co., Ltd.

Reddy’s Laboratories Ltd. ##. ##. ##. ## Company overview ##. ##. ##. ## Financial performance ##. ##. ##. ## Product benchmarking ##. ##. ##. ## Strategic initiatives List of Tables TABLE ## Country share estimation TABLE ## North America erythropoietin drugs market, by country, 2014 - 2025 (USD Million) T

  • Biopharmaceutical
  • Erythropoietin
  • United States
  • Forecast

Global Erythropoietin Market Outlook 2020 ##.

  • Biopharmaceutical
  • Erythropoietin
  • World
  • Market Size
  • ERYTHROPOIETIN - DRUG PROFILE
  • PHEP-01 - DRUG PROFILE

Chemotherapy Induced Anemia - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Anemia - Pipeline Review, H1 2018, provides an overview of the Chemotherapy Induced Anemia (Toxicology) pipeline landscape. Chemotherapy-induced...

  • Chemotherapy
  • Erythropoietin
  • Japan
  • United States
  • World
  • PEGYLATED ERYTHROPOIETIN - DRUG PROFILE
  • PHEP-01 - DRUG PROFILE

Chemotherapy Induced Anemia - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Anemia - Pipeline Review, H2 2017, provides an overview of the Chemotherapy Induced Anemia (Toxicology) pipeline landscape. Chemotherapy-induced...

  • Blood Disease
  • Chemotherapy
  • Erythropoietin
  • Oncology
  • Tolero Pharmaceuticals, Inc.
  • ERYTHROPOIETIN - DRUG PROFILE
  • R&D Progress

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H2 2017, provides an overview of the Anemia in Chronic Kidney Disease...

  • Chronic Disease
  • Erythropoietin
  • Japan
  • United States
  • Product Initiative
  • PEGYLATED ERYTHROPOIETIN - DRUG PROFILE
  • ERYTHROPOIETIN - DRUG PROFILE

Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2017, provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological...

  • Blood Disease
  • Erythropoietin
  • Pharmaceutical
  • United States
  • Product Initiative
  • 8.4 ERYTHROPOIETIN (EPO)
  • PEGYLATED PROTEINS MARKET SIZE FOR ERYTHROPOIETIN, BY REGION, 2014-2021 (USD MILLION)

The global PEGylated proteins market is expected to USD 1,137.8 million by 2021 from USD 690.6 million in 2016, at a CAGR of 10.5% between 2016 and 2021. The growth of this market is mainly driven by increase in R&D spending of pharmaceutical & biotechnology companies, growth in biologics sector, high prevalence of lifestyle disease, and increase...

  • Erythropoietin
  • North America
  • United States
  • Market Size
  • JenKem Technology Co., Ltd
  • Erythropoietin: An overview
  • Global erythropoietin market

About the Recombinant Human Erythropoietin (rhEPO) Market in China Erythropoietin (EPO), also referred to as hematopoietin or hemopoietin, is a glycoprotein responsible for producing erythrocytes in the body. In the fetal stage, this protein is produced in the liver; it is secreted by the kidneys in adulthood. During anemic conditions,...

  • Erythropoietin
  • China
  • Market Size
  • 3SBio Inc.
  • Kyowa Hakko Kirin Co., Ltd.
  • R&D Progress Research and Development Brief
  • Licensing and Collaboration

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2017 Summary Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) pipeline Target constitutes close to 8 molecules. Out of which approximately...

  • Erythropoietin
  • China
  • United States
  • Product Initiative
  • FibroGen, Inc.
  • 53.52% OF THE MARKET SHARE COMES FROM GLOBAL MABS MARKET

About Protein Therapeutics Therapeutic proteins are used to effectively treat a wide array of diseases such as protein deficiency diseases; chronic diseases such as cancer, rheumatoid arthritis (RA), ankylosing spondylitis, diabetes; infections such as human immunodeficiency virus (HIV), hepatitis A, hepatitis B, and hepatitis C; and other...

  • Erythropoietin
  • AbbVie Inc.
  • Amgen Inc.
  • Merck & Co., Inc.
  • Novo Nordisk Group
  • Clinical Trial profile. 7 Trial Title
  • Clinical Trial profile. 9 Trial Title

Chemotherapy Induced Anemia Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Chemotherapy Induced Anemia Global Clinical Trials Review, H1, 2017" provides an overview of Chemotherapy Induced Anemia clinical trials scenario. This report provides top line data relating to the clinical...

  • Blood Disease
  • Clinical Trial
  • Erythropoietin
  • Therapy
  • Amgen Inc.
  • 3. GDCT ID is the unique ID of GlobalData's Pharma Intelligence Center clinical trial database
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Blood Disease
  • Erythropoietin
  • World
  • Product Initiative
  • F. Hoffmann-La Roche Ltd.
  • Official Title
  • Official Title

Anemia in Chronic Kidney Disease (Renal Anemia) Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Anemia in Chronic Kidney Disease (Renal Anemia) Global Clinical Trials Review, H2, 2016" provides an overview of Anemia in Chronic Kidney Disease (Renal Anemia) clinical trials scenario....

  • Blood Disease
  • Clinical Trial
  • Erythropoietin
  • World
  • Product Initiative
  • FG-6874 - DRUG PROFILE
  • FG-8205 - DRUG PROFILE

Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Transmembrane Prolyl 4-Hydroxylase (Hypoxia-Inducible Factor Prolyl Hydroxylase 4 or EC 1.14.11.) - Pipeline Review, H1 2016’, provides in depth analysis on Transmembrane...

  • Erythropoietin
  • United States
  • World
  • Product Initiative
  • FibroGen, Inc.
  • II. BUSINESS ENVIRONMENT
  • IV

The auto exports exceeded over ## million each year.

  • Biotechnology
  • Erythropoietin
  • China
  • Demand
  • Supply

(USA) ##.

  • Biopharmaceutical
  • Erythropoietin
  • Pathology
  • World
  • Market Shares
  • BBT-009
  • Bolder Biotechnology, Inc. - Preclinical, 2016

Bolder Biotechnology, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Bolder Biotechnology, Inc. - Product Pipeline Review - 2016’, provides an overview of the Bolder Biotechnology, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the...

  • Erythropoietin
  • Growth Hormone
  • United States
  • Company Operations
  • Bolder BioTechnology, Inc.
  • epoetin alfa - Drug Profile

Erythropoietin (EPO) binds with erythropoietin receptors expressed in brain tissue and their expression increases during ischemia suggesting a role in endogenous neuroprotective system.

  • Erythropoietin
  • Japan
  • Company Operations
  • Product Initiative
  • R-Tech Ueno, Ltd.

(USA) ##.

  • Erythropoietin
  • China
  • United States
  • World
  • Market Shares

(Israel) ##.

  • Biopharmaceutical
  • Erythropoietin
  • Pathology
  • World
  • Market Shares

(France) ##.

  • Erythropoietin
  • Pharmaceutical
  • United States
  • World
  • Market Shares
  • EPOETIN ALFA - DRUG PROFILE
  • PEG-EPO - DRUG PROFILE

Renal Anemia - Pipeline Review, H2 2015 Summary Global Markets Direct’s, ‘Renal Anemia - Pipeline Review, H2 2015’, provides an overview of the Renal Anemia’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis...

  • Blood Disease
  • Erythropoietin
  • United States
  • Company Operations
  • FibroGen, Inc.